Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
eqs_en 
0 01.05.23
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
eqs_en 
0 01.05.23
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
eqs_en 
0 30.04.23
Abivax postpones the publication of its 2023 Universal Registration Document
Abivax postpones the publication of its 2023 Universal Registration Document
Abivax postpones the publication of its 2023 Universal Registration Document
eqs_en 
0 28.04.23
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
eqs_en 
0 28.04.23
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
eqs_en 
0 28.04.23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
eqs_en 
0 28.04.23
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
eqs_en 
0 28.04.23
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
eqs_en 
0 27.04.23
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
eqs_en 
0 27.04.23
EQS-News: Formycon publishes results for financial year 2022
EQS-News: Formycon publishes results for financial year 2022
EQS-News: Formycon publishes results for financial year 2022
eqs_en 
0 27.04.23
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
eqs_en 
0 27.04.23
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
eqs_en 
0 26.04.23
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
eqs_en 
0 26.04.23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
eqs_en 
0 26.04.23
Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
eqs_en 
0 26.04.23
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
eqs_en 
0 25.04.23
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
eqs_en 
0 25.04.23
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
eqs_en 
0 25.04.23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
eqs_en 
0 25.04.23
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
eqs_en 
0 25.04.23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
eqs_en 
0 24.04.23
Evolva publishes timeline of the Reverse Stock Split
Evolva publishes timeline of the Reverse Stock Split
Evolva publishes timeline of the Reverse Stock Split
eqs_en 
0 24.04.23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
eqs_en 
0 21.04.23
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
eqs_en 
0 21.04.23